心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2021 专家共识：高尿酸血症和高心血管风险患者的诊断和治疗（更新版）

2021-01-13 国外心血管相关专家小组（统称） Cardiol J . 2021 Jan 13.

心血管风险高尿酸血症

本文是对2018年高尿酸血症和高心血管风险患者的诊断和治疗共识的更新。在管理策略部分主要更新了血尿酸水平升高患者治疗的5步建议。

中文标题：

2021 专家共识：高尿酸血症和高心血管风险患者的诊断和治疗（更新版）

英文标题：

Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update

发布机构：

国外心血管相关专家小组（统称）

发布日期：

2021-01-13

简要介绍：

本文是对2018年高尿酸血症和高心血管风险患者的诊断和治疗共识的更新。在管理策略部分主要更新了血尿酸水平升高患者治疗的5步建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 专家共识：高尿酸血症和高心血管风险患者的诊断和治疗（更新版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=1bee21c00203e911, title=2021 专家共识：高尿酸血症和高心血管风险患者的诊断和治疗（更新版）, enTitle=Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update, guiderFrom=Cardiol J . 2021 Jan 13., authorId=0, author=, summary=本文是对2018年高尿酸血症和高心血管风险患者的诊断和治疗共识的更新。在管理策略部分主要更新了血尿酸水平升高患者治疗的5步建议。, cover=https://img.medsci.cn/2021118/1610984758332_2020535.jpg, journalId=0, articlesId=null, associationId=738, associationName=国外心血管相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Wed Jan 13 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>本文是对2018年高尿酸血症和高心血管风险患者的诊断和治疗共识的更新。在管理策略部分主要更新了血尿酸水平升高患者治疗的5步建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=1567, tagName=心血管风险), TagDto(tagId=4057, tagName=高尿酸血症)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=4057, guiderKeyword=高尿酸血症, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5194, appHits=545, showAppHits=0, pcHits=1695, showPcHits=4647, likes=6, shares=51, comments=23, approvalStatus=1, publishedTime=Tue Jan 19 00:12:33 CST 2021, publishedTimeString=2021-01-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Jan 18 23:46:08 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 14:37:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 专家共识：高尿酸血症和高心血管风险患者的诊断和治疗（更新版）.pdf)])
2021 专家共识：高尿酸血症和高心血管风险患者的诊断和治疗（更新版）.pdf
下载请点击：
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1216742, encodeId=5a081216e4223, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45258146887, createdName=ms9000000962048417, createdTime=Wed May 04 11:17:44 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205803, encodeId=e7cd1205803e2, content=学指南，用指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e46488127, createdName=ms3000000235780593, createdTime=Fri Mar 25 10:50:54 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184713, encodeId=e6fd1184e1320, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220116/72e91e7990f7455db4693ee7aeff8937/30cd494ac4214e05b38c2d6fadfa8410.jpg, createdBy=43bf2028192, createdName=1e22b426m70(暂无匿称), createdTime=Sat Jan 15 23:52:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184648, encodeId=cab11184648ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0391651C5784486DC064FF0CC8D8CF2C/100, createdBy=df4d2418589, createdName=高寒, createdTime=Sat Jan 15 20:51:12 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183595, encodeId=84f71183595b4, content=没有积分，所以没看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48782851574, createdName=1768748865, createdTime=Wed Jan 12 18:22:47 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-05-04 ms9000000962048417

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1216742, encodeId=5a081216e4223, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45258146887, createdName=ms9000000962048417, createdTime=Wed May 04 11:17:44 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205803, encodeId=e7cd1205803e2, content=学指南，用指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e46488127, createdName=ms3000000235780593, createdTime=Fri Mar 25 10:50:54 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184713, encodeId=e6fd1184e1320, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220116/72e91e7990f7455db4693ee7aeff8937/30cd494ac4214e05b38c2d6fadfa8410.jpg, createdBy=43bf2028192, createdName=1e22b426m70(暂无匿称), createdTime=Sat Jan 15 23:52:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184648, encodeId=cab11184648ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0391651C5784486DC064FF0CC8D8CF2C/100, createdBy=df4d2418589, createdName=高寒, createdTime=Sat Jan 15 20:51:12 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183595, encodeId=84f71183595b4, content=没有积分，所以没看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48782851574, createdName=1768748865, createdTime=Wed Jan 12 18:22:47 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-03-25 ms3000000235780593

    学指南，用指南

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1216742, encodeId=5a081216e4223, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45258146887, createdName=ms9000000962048417, createdTime=Wed May 04 11:17:44 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205803, encodeId=e7cd1205803e2, content=学指南，用指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e46488127, createdName=ms3000000235780593, createdTime=Fri Mar 25 10:50:54 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184713, encodeId=e6fd1184e1320, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220116/72e91e7990f7455db4693ee7aeff8937/30cd494ac4214e05b38c2d6fadfa8410.jpg, createdBy=43bf2028192, createdName=1e22b426m70(暂无匿称), createdTime=Sat Jan 15 23:52:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184648, encodeId=cab11184648ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0391651C5784486DC064FF0CC8D8CF2C/100, createdBy=df4d2418589, createdName=高寒, createdTime=Sat Jan 15 20:51:12 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183595, encodeId=84f71183595b4, content=没有积分，所以没看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48782851574, createdName=1768748865, createdTime=Wed Jan 12 18:22:47 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-15 1e22b426m70(暂无匿称)

    学习学习！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1216742, encodeId=5a081216e4223, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45258146887, createdName=ms9000000962048417, createdTime=Wed May 04 11:17:44 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205803, encodeId=e7cd1205803e2, content=学指南，用指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e46488127, createdName=ms3000000235780593, createdTime=Fri Mar 25 10:50:54 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184713, encodeId=e6fd1184e1320, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220116/72e91e7990f7455db4693ee7aeff8937/30cd494ac4214e05b38c2d6fadfa8410.jpg, createdBy=43bf2028192, createdName=1e22b426m70(暂无匿称), createdTime=Sat Jan 15 23:52:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184648, encodeId=cab11184648ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0391651C5784486DC064FF0CC8D8CF2C/100, createdBy=df4d2418589, createdName=高寒, createdTime=Sat Jan 15 20:51:12 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183595, encodeId=84f71183595b4, content=没有积分，所以没看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48782851574, createdName=1768748865, createdTime=Wed Jan 12 18:22:47 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-15 高寒

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1216742, encodeId=5a081216e4223, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45258146887, createdName=ms9000000962048417, createdTime=Wed May 04 11:17:44 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205803, encodeId=e7cd1205803e2, content=学指南，用指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48e46488127, createdName=ms3000000235780593, createdTime=Fri Mar 25 10:50:54 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184713, encodeId=e6fd1184e1320, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220116/72e91e7990f7455db4693ee7aeff8937/30cd494ac4214e05b38c2d6fadfa8410.jpg, createdBy=43bf2028192, createdName=1e22b426m70(暂无匿称), createdTime=Sat Jan 15 23:52:26 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184648, encodeId=cab11184648ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0391651C5784486DC064FF0CC8D8CF2C/100, createdBy=df4d2418589, createdName=高寒, createdTime=Sat Jan 15 20:51:12 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183595, encodeId=84f71183595b4, content=没有积分，所以没看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48782851574, createdName=1768748865, createdTime=Wed Jan 12 18:22:47 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-12 1768748865

    没有积分，所以没看到

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2020 ACC专家共识：降低2型糖尿病患者心血管风险的新型疗法决策路径

美国心脏病学会(ACC,American College of Cardiology) · 2020-08-05

2019 AHA科学建议：膳食胆固醇与心血管风险

美国心脏协会(AHA,American Heart Association) · 2019-12-16

2019 AHA科学声明：降低高危儿科患者心血管风险

美国心脏协会(AHA,American Heart Association) · 2019-02-25

2018 ACC专家共识：降低2型糖尿病以及粥样硬化性心血管疾病患者心血管风险的新型治疗决策路径

美国心脏病学会(ACC,American College of Cardiology) · 2018-11-26

2018 专家共识：高尿酸血症和高心血管风险患者的诊断和治疗

国外心血管相关专家小组（统称） · 2018-10-30

高甘油三酯血症及其心血管风险管理专家共识

中国胆固醇教育计划委员会 · 2017-02-20

拓展阅读

高尿酸血症和痛风治疗的中国专家共识

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2013-11-01

中国肾脏疾病高尿酸血症诊治的实践指南（2017版）

中国医师协会肾内科医师分会 · 2017-07-04

中国高尿酸血症相关疾病诊疗多学科专家共识

肾脏病相关专家小组（统称） · 2017-03-30

中国慢性肾脏病患者合并高尿酸血症诊治专家共识

中国慢性肾脏病患者合并高尿酸血症诊治共识专家组 · 2017-06-30

中国高尿酸血症与相关疾病诊疗多学科专家共识（英文版）

肾脏病相关专家小组（统称） · 2017-10-20

2018 台湾多学科共识：痛风及高尿酸血症的管理

台湾多学科工作组（统称） · 2018-01-24